SC
GILD icon

SummitTX Capital’s Gilead Sciences GILD Stock Holding History

SummitTX Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.25M Buy
+41,589
New +$5.48M 0.14% 180
2025
Q4 		– Sell
-74,476
Closed -$8.27M – 803
2025
Q3 		$8.27M Buy
74,476
+6,928
+10% +$787K 0.34% 65
2025
Q2 		$7.49M Buy
67,548
+61,164
+958% +$6.51M 0.32% 67
2025
Q1 		$715K Buy
+6,384
New +$659K 0.03% 464

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SummitTX Capital's GILD Position: Q2 2026 in Review

SummitTX Capital opened a new position in Gilead Sciences (GILD) in Q2 2026: 41,589 shares worth $5.25M. The stake represents 0.14% of the portfolio and ranks #180 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in GILD as recently as Q3 2025.

SummitTX Capital first reported a position in GILD in Q1 2025 and has held it in 4 quarters since. The position peaked at $8.27M in Q3 2025. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • SummitTX Capital held 41,589 shares of Gilead Sciences worth $5.25M as of Q2 2026.
  • Gilead Sciences was a new SummitTX Capital position in Q2 2026.
  • Gilead Sciences made up 0.14% of SummitTX Capital's portfolio in Q2 2026, its #180 holding.
  • SummitTX Capital first reported a position in Gilead Sciences in Q1 2025 and has held it in 4 quarters since.
  • SummitTX Capital's Gilead Sciences position peaked at $8.27M in Q3 2025.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.